文献速递流行病学与生物统计真实世界研究与卫生经济

COVID-19胃肠道预防用药:观察性研究中不当对照选择导致严重偏倚的示例

Gastrointestinal prophylaxis for COVID-19: an illustration of severe bias arising from inappropriate comparators in observational studies.
PubMed 文献 · J Clin Epidemiol · 2022-07-20

本研究纳入2020年3月至11月3804例≥18岁COVID-19住院患者,采用倾向评分精细分层比较不同胃肠道预防用药对临床改善的影响。在合适对照比较中,法莫替丁与奥美拉唑、或静脉法莫替丁与静脉泮托拉唑之间均未发现获益;而在ICU中用户与非用户的不当比较中,法莫替丁用户改善概率降低32%-45%,奥美拉唑或泮托拉唑用户降低21%-48%。结论提示不当对照选择可在危重患者中产生虚假关联。

要点

  • 合适对照比较中,COVID-19住院患者使用胃肠道预防用药未显示临床改善获益。
  • ICU中用户与非用户的不当比较显示法莫替丁用户改善概率降低32%-45%。
  • ICU中奥美拉唑或泮托拉唑用户与非用户不当比较显示改善概率降低21%-48%。

核心结论

  • 在设置适当的比较中,未发现胃肠道预防用药改善COVID-19住院患者结局的证据。
  • 不当的对照选择可在危重患者中导致虚假关联。

研究设计与样本

  • 研究识别了2020年3月至11月期间3804例年龄≥18岁的COVID-19住院患者。
  • 比较不同胃保护剂对COVID-19临床改善的影响,采用已发表的严重程度量表测量。
  • 使用基于倾向评分的精细分层进行混杂调整。
  • 根据指南预设了临床均势药物间的比较,以及ICU中胃肠道预防用药用户与非用户的不当比较。

主要发现

  • 在普通病房或ICU患者中,口服法莫替丁与奥美拉唑比较未检测到获益。
  • 静脉法莫替丁与静脉泮托拉唑比较也未发现关联。
  • 在ICU用户与非用户的不当比较中,法莫替丁用户改善概率降低32%-45%。
  • 在ICU用户与非用户的不当比较中,奥美拉唑或泮托拉唑用户改善概率降低21%-48%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We aimed to use setting-appropriate comparisons to estimate the effects of different gastrointestinal (GI) prophylaxis pharmacotherapies for patients hospitalized with COVID-19 and setting-inappropriate comparisons to illustrate how improper design choices could result in biased results. STUDY DESIGN AND SETTING: We identified 3,804 hospitalized patients aged ≥ 18 years with COVID-19 from March to November 2020. We compared the effects of different gastroprotective agents on clinical improvement of COVID-19, as measured by a published severity scale. We used propensity score-based fine-stratification for confounding adjustment. Based on guidelines, we prespecified comparisons between agents with clinical equipoise and inappropriate comparisons of users vs. nonusers of GI prophylaxis in the intensive care unit (ICU). RESULTS: No benefit was detected when comparing oral famotidine to omeprazole in patients treated in the general ward or ICUs. We also found no associations when comparing intravenous famotidine to intravenous pantoprazole. For inappropriate comparisons of users vs. nonusers in the ICU, the probability of improvement was reduced by 32%-45% in famotidine users and 21%-48% in omeprazole or pantoprazole users. CONCLUSION: We found no evidence that GI prophylaxis improved outcomes for patients hospitalized with COVID-19 in setting-appropriate comparisons. An improper comparator choice can lead to spurious associations in critically ill patients.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Lin KJ, Feldman WB, Wang SV, et al. Gastrointestinal prophylaxis for COVID-19: an illustration of severe bias arising from inappropriate comparators in observational studies. J Clin Epidemiol. 2022. PMID: 35868493. doi:10.1016/j.jclinepi.2022.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。